#1 Clinical Trials Search in Europe

Human Papillomavirus Type 31 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 31 L1 Protein vaccine, a component of the 9-valent HPV (9vHPV) vaccine. These studies aim to evaluate the vaccine’s efficacy, safety, and immunogenicity in various populations and conditions, including extended dosing intervals, immunocompromised patients, and treatment of HPV-related lesions. The trials cover different age groups and explore potential new applications of the vaccine beyond its current approved uses.

Table of Contents

What is Human Papillomavirus Type 31 L1 Protein?

Human Papillomavirus Type 31 L1 Protein is one of the components of the 9-valent HPV vaccine, also known as Gardasil 9. This vaccine is designed to prevent infections and diseases caused by nine types of human papillomavirus (HPV), including type 31.[1] HPV is a common sexually transmitted infection that can lead to various health problems, including certain types of cancer.

Vaccine Composition and Mechanism

The vaccine contains virus-like particles (VLPs) of the L1 protein from nine different HPV types, including type 31. These VLPs are produced in yeast cells (Saccharomyces cerevisiae) using recombinant DNA technology.[1] The L1 protein is the major capsid protein of HPV, which forms the outer shell of the virus. By introducing these proteins into the body, the vaccine stimulates an immune response without causing an actual HPV infection.

In addition to HPV type 31, the vaccine includes L1 proteins from HPV types 6, 11, 16, 18, 33, 45, 52, and 58. Each of these components is adsorbed onto an aluminum-containing adjuvant, which helps enhance the immune response.[1]

Diseases Prevented

The 9-valent HPV vaccine, which includes the HPV Type 31 L1 Protein, is designed to prevent several HPV-related conditions:[1]

  • Persistent anogenital HPV infection
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV Types 6 and 11
  • Precancerous or dysplastic lesions caused by the nine HPV types covered by the vaccine

Administration and Dosing

The vaccine is administered as an intramuscular injection, typically in the upper arm or thigh. The standard dosing schedule varies depending on the age at which vaccination is initiated:[1]

  • For individuals 9-14 years old: Two doses, with the second dose given 6-12 months after the first
  • For individuals 15 years and older: Three doses, with the second dose given 2 months after the first, and the third dose given 6 months after the first

Some studies are investigating extended dosing intervals and their impact on vaccine efficacy.[1]

Efficacy and Immune Response

Clinical trials have shown that the 9-valent HPV vaccine, including the HPV Type 31 L1 Protein component, is highly effective in preventing HPV infections and related diseases. The vaccine stimulates the production of antibodies against the nine HPV types it covers.[1]

Efficacy is measured through several endpoints, including:

  • Seroconversion rates (the percentage of individuals who develop detectable antibodies after vaccination)
  • Geometric Mean Titers (GMTs) of antibodies
  • Incidence of persistent HPV infections
  • Incidence of HPV-related precancerous lesions and cancers

Studies have shown high seroconversion rates and strong antibody responses to all nine HPV types covered by the vaccine, including type 31.[1]

Safety Profile

The 9-valent HPV vaccine, including the HPV Type 31 L1 Protein component, has been extensively tested and is generally considered safe. Common side effects may include:[1]

  • Pain, swelling, and redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious adverse events are rare. As with any vaccine, there is a small risk of allergic reactions. Individuals with known allergies to any vaccine components should not receive the vaccine.[1]

Use in Special Populations

Research is ongoing to evaluate the use of the 9-valent HPV vaccine in various populations:

  • Immunocompromised individuals: Studies are investigating the vaccine’s immunogenicity and safety in people with compromised immune systems, such as those with HIV or organ transplant recipients.[2]
  • Adult males: Research is exploring the vaccine’s efficacy in preventing oral HPV infections in men aged 20-45 years.[3]
  • Women over 45: Studies are evaluating the vaccine’s potential in preventing HPV infections and related diseases in older women.[4]

Ongoing Research

Several clinical trials are currently underway to further investigate the 9-valent HPV vaccine, including its HPV Type 31 L1 Protein component:

  • Extended dosing intervals: Researchers are studying the safety and immunogenicity of 2-dose regimens with longer intervals between doses in children and adolescents.[1]
  • Therapeutic use: Some studies are exploring the vaccine’s potential in treating existing HPV-related conditions, such as difficult-to-treat warts.[5]
  • Prevention of recurrence: Research is investigating whether vaccination can prevent the recurrence of high-grade cervical lesions in women who have undergone treatment.[4]

These ongoing studies aim to optimize the use of the vaccine and potentially expand its applications in preventing and treating HPV-related diseases.

Study Focus Target Population Key Objectives Primary Endpoints
Extended dosing intervals Children and adolescents 9-14 years, young women 16-26 years Evaluate safety and immunogenicity of 2-dose vs 3-dose regimens Antibody levels (GMTs) at 4 weeks post-last dose
Immunocompromised patients Children and adolescents 9-18 years post-transplant or chemotherapy Assess vaccine response in immunocompromised individuals Seroconversion rates at 7 months
Adult males oral HPV prevention Males 20-45 years Evaluate efficacy in preventing oral HPV infection Incidence of HPV-related oral persistent infection
Vulvar HSIL treatment Women with vulvar high-grade squamous intraepithelial lesions Assess vaccine efficacy in preventing HSIL recurrence Clinical recurrence rate of vulvar HSIL at 24 months
Post-cervical lesion treatment Women over 45 years treated for high-grade cervical lesions Evaluate vaccine effect on HPV clearance HPV-negative status within 24 months
Palmar/plantar wart treatment Patients ≥15 years with difficult-to-treat warts Assess vaccine efficacy in treating resistant warts Complete remission of warts at 7 months

FAQ

  • What is the main purpose of these clinical trials? The main purpose of these clinical trials is to evaluate the efficacy, safety, and immunogenicity of the 9-valent HPV vaccine, which contains Human Papillomavirus Type 31 L1 Protein, in various populations and conditions. The studies aim to explore new dosing regimens, assess the vaccine's effectiveness in immunocompromised patients, and investigate its potential use in treating HPV-related lesions.
  • Who are the target populations for these studies? The target populations vary across the studies but include children and adolescents aged 9-14, adults aged 16-26, immunocompromised patients, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), and individuals with difficult-to-treat palmar or plantar warts. Some studies also focus on specific groups such as stem cell transplant recipients and patients treated for high-grade cervical lesions.
  • What are some of the key outcomes being measured in these trials? Key outcomes being measured include antibody responses to HPV types, seroconversion rates, incidence of HPV-related infections and lesions, safety and tolerability of the vaccine, quality of life improvements, and in some cases, clearance of existing HPV infections or warts. Some studies also assess the vaccine's effectiveness in preventing recurrence of high-grade lesions.
  • How long do these clinical trials typically last? The duration of these clinical trials varies, but many of them involve follow-up periods ranging from 12 months to several years. Some studies have primary endpoints at 7 months after the first vaccination, while others track participants for up to 5 or even 10 years to assess long-term outcomes and effectiveness.
  • Are there any new applications of the HPV vaccine being explored in these trials? Yes, some of the trials are exploring new applications of the HPV vaccine. These include using the vaccine to treat difficult-to-treat palmar or plantar warts, evaluating its effectiveness in preventing recurrence of vulvar high-grade squamous intraepithelial lesions (vHSIL), and assessing its potential in clearing persistent HPV infections in women over 45 years old who have been treated for high-grade cervical lesions.

Ongoing Clinical Trials on Human Papillomavirus Type 31 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, and some are targeted by vaccines to prevent infection.
  • 9-valent HPV vaccine (9vHPV): A vaccine that protects against nine types of HPV, including types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is designed to prevent HPV-related cancers and genital warts.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response to vaccination or infection.
  • Geometric Mean Titer (GMT): A measure of the average concentration of antibodies in a group of samples, used to assess the strength of the immune response to a vaccine.
  • High-grade Squamous Intraepithelial Lesion (HSIL): Abnormal, precancerous changes in the cells of the cervix, vulva, or other areas that may progress to cancer if left untreated.
  • Allogeneic Stem Cell Transplantation (AlloSCT): A procedure where stem cells from a matched donor are transplanted into a patient to treat certain blood and immune system disorders.
  • Competitive Luminex Immunoassay (cLIA): A laboratory test used to measure antibody levels in response to vaccination or infection.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of Life (QoL): A measure of an individual's overall well-being, including physical, mental, and social aspects of health.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/
  5. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/